Traditional MedicareCoverageMedium impact
MolDX: Envisia™, Veracyte™, Idiopathic Pulmonary Fibrosis Diagnostic Test
Medicare/CMS - LCD·Pulmonology·Local Coverage Determination
Effective date
May 28, 2026
We identified it
Jun 17, 2026
Summary
New Medicare coverage determination establishes specific criteria for the Envisia diagnostic test used to diagnose idiopathic pulmonary fibrosis. This affects pulmonology practices that order this specialized genomic test for lung disease diagnosis.
Action Required
By May 28, 2026: Pulmonology providers must review new coverage criteria for Envisia IPF diagnostic test orders. Update prior authorization processes if required and ensure documentation meets Medicare requirements for this molecular diagnostic test. Billing team should verify coverage determination details from CGS Administrators before processing claims.